Table 2.
Mean values and changes from baseline after 4 weeks in exploratory biochemical parameters during treatment with dapagliflozin, eplerenone, or dapagliflozin-eplerenone
| Parameter | Dapagliflozin | Eplerenone | Dapagliflozin/Eplerenone |
|---|---|---|---|
| HbA1c, mmol/mol | |||
| Baseline | 48.9 (1.7) | 49.5 (1.7) | 50 (1.7) |
| Week 4 | 48.2 (1.7) | 50.3 (1.7) | 49.6 (1.7) |
| Change from baseline | −0.7 (0.5) | 0.7 (0.5) | −0.5 (0.5) |
| P value | 0.16 | 0.16 | 0.37 |
| Body weight, kg | |||
| Baseline mean | 85.8 (2.9) | 86 (2.9) | 86.4 (2.9) |
| Week 4 mean | 85 (2.9) | 85.6 (2.9) | 85.3 (2.9) |
| Change from baseline | −0.8 (0.3) | −0.4 (0.3) | −1 (0.3) |
| P value | 0.01 | 0.18 | <0.001 |
| Hemoglobin, g/dl | |||
| Baseline mean | 13.7 (0.3) | 13.9 (0.3) | 13.7 (0.3) |
| Week 4 mean | 14.1 (0.3) | 13.9 (0.3) | 14.1 (0.3) |
| Change from baseline | 0.37 (0.1) | −0.04 (0.1) | 0.36 (0.1) |
| P value | 0.002 | 0.73 | 0.003 |
| Hematocrit, % | |||
| Baseline mean | 42 (0.7) | 42.6 (0.8) | 41.9 (0.8) |
| Week 4 mean | 43.5 (0.7) | 42.3 (0.7) | 42.8 (0.7) |
| Change from baseline | 1.5 (0.3) | −0.2 (0.3) | 0.8 (0.3) |
| P value | <0.001 | 0.52 | 0.02 |
| NT-proBNP, pg/ml | |||
| Baseline mean | 93.9 (14.7) | 72.8 (12.2) | 78.3 (13.2) |
| Week 4 mean | 74.5 (12.4) | 59.1 (9.9) | 62.2 (10.4) |
| Change from baseline | −19.4 (6.6) | −13.7 (5.1) | −16.1 (5.6) |
| P value | 0.004 | 0.008 | 0.004 |
| Fractional Na+ excretion, % | |||
| Baseline mean | 0.75 (0.06) | 0.78 (0.07) | 0.73 (0.07) |
| Week 4 mean | 0.87 (0.06) | 0.93 (0.07) | 0.96 (0.07) |
| Change from baseline | 0.12 (0.05) | 0.17 (0.05) | 0.21 (0.05) |
| P value | 0.03 | 0.003 | <0.001 |
| Fractional K+ excretion, % | |||
| Baseline mean | 8.9 (0.6) | 9.2 (0.6) | 9.4 (0.6) |
| Week 4 mean | 10.5 (0.6) | 9.8 (0.6) | 10 (0.6) |
| Change from baseline | 1.4 (0.5) | 0.7 (0.5) | 0.7 (0.5) |
| P value | 0.006 | 0.20 | 0.16 |
Shown are mean and standard errors except for NT-proBNP, which is reported as geometric mean.